Marketed in 60 countries across Europe, the Americas, the Middle East, and Asia-Pacific, Lamisil is a globally distributed brand of terbinafine hydrochloride, classified as a broad-spectrum antifungal. For travellers and expatriates who already know Lamisil from a pharmacy at home, the brand turns up in an unusually wide range of markets — which is part of why this page exists, to help readers confirm whether the product they are looking at abroad is the same medication they recognise.
Lamisil is prescribed for the management of fungal infections, including conditions caused by dermatophytes and certain yeast-related infections such as vaginal candidiasis. The complete list of registered indications, which can vary slightly between regulators, is shown in the structured data block further down this page.
Because Lamisil is so broadly registered, the same medication can appear under the Lamisil name in some countries and as a terbinafine generic in others. Markets where the brand is registered include Brazil, Australia, China, Canada, and Belgium, but packaging, prescription pathways, and over-the-counter status differ from one regulatory regime to another. A pharmacist in the destination country can confirm whether a locally stocked terbinafine product corresponds to the Lamisil a traveller is already familiar with.
Other medications in the broad-spectrum antifungal class are sold internationally under different molecules and brand names, intended for overlapping but not identical clinical situations. Travellers and expatriates trying to identify a local equivalent should treat the question as a clinical one rather than a shelf-matching exercise: a healthcare provider familiar with the patient's situation is best placed to advise on whether terbinafine — or another antifungal — is the appropriate choice in a given country.
Lamisil is prescribed for the management of fungal infections, including dermatophyte-related infections and vaginal candidiasis. As a broad-spectrum antifungal, it addresses a range of fungal organisms rather than a single species, which is reflected in its registered indications across different markets. The structured indication block below this introduction lists each registered use in the countries where Lamisil is authorised for sale.
Lamisil contains terbinafine hydrochloride, classified as a broad-spectrum antifungal. Terbinafine is the same molecule whether sold under the Lamisil brand or as a generic product — internationally, the same active ingredient circulates under multiple commercial names, particularly in markets where the original patent has expired and several manufacturers produce terbinafine-containing products in parallel.
Lamisil is registered in 60 countries, spanning Europe, the Americas, the Middle East, and Asia-Pacific. Examples include Brazil, Australia, Canada, China, Denmark, Bahrain, and Argentina. If your country is not on this list, a local pharmacist can usually confirm whether terbinafine is available in that market under a different brand name or as a generic preparation.
Terbinafine is sold under several brand names worldwide, particularly in markets where the original patent has expired, and generic terbinafine products are widely available. Other medications within the broad-spectrum antifungal class also exist, although molecules within the class are not freely interchangeable. To identify a local terbinafine-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Antifungal therapy is calibrated to the specific type of infection, its location, and the patient's broader clinical context, and prescription rules for terbinafine differ between countries — in some markets it requires a prescription, in others certain forms are available over the counter. Travellers and expatriates trying to start, continue, or substitute Lamisil should involve a healthcare provider rather than relying on brand familiarity alone.
